Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] — Patent Landscape

Aggregated US Orange Book patent estate across every drug in the human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor [epc] class. 35 active patents protecting 3 drugs. First major cliff: 2032. Daily refresh.

3
Drugs in class
35
Active US patents
55/100
Avg vulnerability
$2.4B
Annual revenue covered

Originators

Gilead Sciences 13 patents

Cliff calendar — next 15 years

12
32
17
33
4
35
2
36

Drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
BICTEGRAVIR SODIUM — 18 41 — 2032-08-15
Emtriva
EMTRICITABINE
 Gilead Sciences 13 62 $2.4B 2032-08-15
TENOFOVIR ALAFENAMIDE FUMARATE — 4 62 — 2032-08-15

Most attackable patents

Patent Drug Type Vuln Expiry
8754065 Emtriva method of use 70 2032-08-15
9296769 Emtriva method of use 70 2032-08-15
8754065 Emtriva method of use 62 2032-08-15
9296769 Emtriva method of use 62 2032-08-15
9296769 BICTEGRAVIR SODIUM method of use 62 2032-08-15
9296769 Emtriva method of use 62 2032-08-15
8754065 BICTEGRAVIR SODIUM method of use 62 2032-08-15
8754065 BICTEGRAVIR SODIUM method of use 62 2032-08-15
9296769 BICTEGRAVIR SODIUM method of use 62 2032-08-15
8754065 Emtriva method of use 62 2032-08-15

Strongest defences

Patent Drug Type Vuln Expiry
9708342 BICTEGRAVIR SODIUM composition of matter 4 2035-06-19
9708342 BICTEGRAVIR SODIUM composition of matter 4 2035-06-19
9216996 BICTEGRAVIR SODIUM composition of matter 4 2033-12-19
9732092 BICTEGRAVIR SODIUM composition of matter 4 2033-12-19
9732092 BICTEGRAVIR SODIUM composition of matter 4 2033-12-19
9216996 BICTEGRAVIR SODIUM composition of matter 4 2033-12-19
10548846 BICTEGRAVIR SODIUM formulation 42 2036-11-08
10857102 Emtriva formulation 42 2033-01-14
11744802 BICTEGRAVIR SODIUM formulation 50 2036-11-08
10385067 BICTEGRAVIR SODIUM method of use 62 2035-06-19

Related